Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas

Journal of Immunological Methods
Paul V BeumRonald P Taylor

Abstract

Rituximab (RTX) is a monoclonal antibody which targets CD20 and is approved for treatment of non-Hodgkin's lymphoma (NHL), with an approximate 50% overall response rate among NHL patients. Accurate determination of RTX concentrations in patient plasmas is important for proper dosing of patients and for correlating RTX concentrations with clinical responses. There is currently no assay available for RTX which utilizes easily obtainable commercial reagents. Therefore, we sought to develop such an assay, and in this report we describe three new assays for RTX concentration. One assay, based on flow cytometry, quantitates immunologically active RTX based on its ability to bind to CD20 on Raji cells. Two other methods, based on flow cytometry and ELISA, measure RTX based on its antigenic properties. The assays are accurate, in good agreement with one another, and can all measure RTX concentrations as low as approximately 1 microg/ml in both sera and plasmas. Use of these assays reveals that chronic lymphocytic leukemia (CLL) patients receiving RTX treatment have lower plasma RTX concentrations than patients with other B cell lymphomas at all times over the usual 4-week course of therapy. The level in CLL plasmas often declines to <1...Continue Reading

References

Mar 31, 2000·Nature Medicine·R A ClynesJ V Ravetch
Aug 25, 2001·Blood·D HuhnUNKNOWN German Chronic Lymphocytic Leukemia Study Group
Jan 17, 2002·Journal of Immunological Methods·Peppy Rebello, Geoff Hale
Mar 26, 2003·Seminars in Oncology·Peter Johnson, Martin Glennie
Sep 17, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wen-Kai Weng, Ronald Levy

❮ Previous
Next ❯

Citations

Jan 21, 2010·Cancer Chemotherapy and Pharmacology·Ana B SanchezBradley T Messmer
Nov 19, 2010·Bioanalysis·Bing KuangHuifen Faye Wang
May 23, 2012·Bioanalysis·Tracey H Clark, Lindsay E King
Jan 1, 2010·Clinical & Developmental Immunology·Giulia MottaAlessio Nencioni
Apr 23, 2013·Expert Opinion on Biological Therapy·Edward M VitalPaul Emery
Jun 16, 2010·Journal of Immunological Methods·G HampsonT M Illidge
Jun 9, 2009·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Enno SchmidtArno Kromminga
Jul 1, 2008·Current Opinion in Immunology·Ronald P Taylor, Margaret A Lindorfer
Jul 27, 2007·Journal of Immunological Methods·H BlascoC Le Guellec
Feb 9, 2007·Critical Reviews in Oncology/hematology·Guillaume CartronChantal Le Guellec
Apr 29, 2015·Molecular Immunology·J M RedmanL M Weiner
Oct 22, 2016·Expert Review of Clinical Pharmacology·Divya SamineniChunze Li
Jan 17, 2014·The Journal of Immunology : Official Journal of the American Association of Immunologists·Nisar A BaigClive S Zent
Aug 3, 2014·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sean H Lim, Ronald Levy
Jan 29, 2016·Clinical Pharmacokinetics·Katherine L GillManoranjenni Chetty
Nov 4, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Michael E WilliamsRonald P Taylor
Jan 18, 2013·Journal of Immunoassay & Immunochemistry·Pavel StrohnerGunther Becher
Jun 21, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jessica L TeelingJan G J van de Winkel
Dec 9, 2020·Biologicals : Journal of the International Association of Biological Standardization·Kavina ShahVenkat Reddy

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.